IOptima (Subsidiary): Renewal of its regulatory approval for marketing and selling the IOPtiMateTM System in China

Tel Aviv (August 27th, 2018) – BioLight is pleased to announce that today, its subsidiary IOPtima Ltd., (“IOptima”) , announced receipt of a renewal of its regulatory approval for marketing and selling the IOPtiMateTM System in China, from the Chinese Food and Drug Administration (“CFDA”), for a period of 5 years until 2023.

IOptima has a distribution agreement in China with the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co with whom a final and binding agreement for the investment in and the acquisition in stages of IOPtima was signed on November 2017.

Link to the complete article

Link to Newsroom

Comments are closed.